T-Cell Lymphoma

>18 yrs; Relapsed or refractory disease second/third line

CCT5041
Phase I
Anti-CD70 CRISPR-Cas9-Engineered TCella(CTX130) in Relapsed/Refractory T/B Cell Malignancies

PI: Weng
Sponsor: CRISPR

KEY
- Pending
- Open for Enrollment
- Observational Study
- Link
- Optional Path
- Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy